The global vildagliptin market is expected to grow at a CAGR of XX% during the forecast period. The growth of the market can be attributed to the increasing prevalence of type 2 diabetes and obesity, which are major risk factors for cardiovascular diseases. The increasing number of people suffering from these conditions is driving the demand for vildagliptin tablets.
The global vildagliptin market is segmented on the basis of type, application, and region. On the basis of type, it is classified into purity greater than or equal to 98%, purity greater than or equal to 99%. On the basis of application, it is classified into vildagliptin tablets. On the basis of region, it is classified into North America (US and Canada), Latin America (Mexico), Europe (Germany and France), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
- Vildagliptin is a drug that is used to treat type 2 diabetes.
- It was approved by the FDA in 2007 and has been on the market since 2008.
- The drug is marketed by Novartis Pharmaceuticals Corporation, which also markets other drugs for diabetes such as Metformin, Glipizide, and Glimepiride.
- The drug works by inhibiting DPP-4 enzyme activity in the pancreas and liver which helps to regulate blood sugar levels in patients with type 2 diabetes mellitus (T2DM).
- Vildagliptin has been shown to be effective at lowering blood sugar levels when taken with metformin or a sulfonylurea medication such as glipizide or glimepiride.
Industry Growth Insights published a new data on “Vildagliptin Market”. The research report is titled “Vildagliptin Market research by Types (PurityGreater than or equal to98%, PurityGreater than or equal to99%), By Applications (Vildagliptin Tablets, Other), By Players/Companies Hikal, Angels Pharma, Beaukev, Chengda Pharmaceuticals, Shanghai Acebright, Ningbo Menovo Pharma, EstechPharma, Megafine, Glenmark Life Sciences, Jubilant Pharma, Hangzhou Longshine Bio-Tech, Zhejiang Zenitech Chemical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vildagliptin Market Research Report
By Type
PurityGreater than or equal to98%, PurityGreater than or equal to99%
By Application
Vildagliptin Tablets, Other
By Companies
Hikal, Angels Pharma, Beaukev, Chengda Pharmaceuticals, Shanghai Acebright, Ningbo Menovo Pharma, EstechPharma, Megafine, Glenmark Life Sciences, Jubilant Pharma, Hangzhou Longshine Bio-Tech, Zhejiang Zenitech Chemical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Vildagliptin Market Report Segments:
The global Vildagliptin market is segmented on the basis of:
Types
PurityGreater than or equal to98%, PurityGreater than or equal to99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Vildagliptin Tablets, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hikal
- Angels Pharma
- Beaukev
- Chengda Pharmaceuticals
- Shanghai Acebright
- Ningbo Menovo Pharma
- EstechPharma
- Megafine
- Glenmark Life Sciences
- Jubilant Pharma
- Hangzhou Longshine Bio-Tech
- Zhejiang Zenitech Chemical
Highlights of The Vildagliptin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PurityGreater than or equal to98%
- PurityGreater than or equal to99%
- By Application:
- Vildagliptin Tablets
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vildagliptin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vildagliptin is a type of diabetes drug that helps to lower blood sugar levels. It is approved by the FDA for the treatment of type 2 diabetes. Vildagliptin works by slowing down the absorption of glucose from the intestines, which lowers blood sugar levels.
Some of the major players in the vildagliptin market are Hikal, Angels Pharma, Beaukev, Chengda Pharmaceuticals, Shanghai Acebright, Ningbo Menovo Pharma, EstechPharma, Megafine, Glenmark Life Sciences, Jubilant Pharma, Hangzhou Longshine Bio-Tech, Zhejiang Zenitech Chemical.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vildagliptin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vildagliptin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vildagliptin Market - Supply Chain
4.5. Global Vildagliptin Market Forecast
4.5.1. Vildagliptin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vildagliptin Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vildagliptin Market Absolute $ Opportunity
5. Global Vildagliptin Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vildagliptin Market Size and Volume Forecast by Type
5.3.1. PurityGreater than or equal to98%
5.3.2. PurityGreater than or equal to99%
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vildagliptin Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vildagliptin Market Size and Volume Forecast by Application
6.3.1. Vildagliptin Tablets
6.3.2. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vildagliptin Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vildagliptin Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vildagliptin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vildagliptin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vildagliptin Demand Share Forecast, 2019-2026
9. North America Vildagliptin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vildagliptin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vildagliptin Market Size and Volume Forecast by Application
9.4.1. Vildagliptin Tablets
9.4.2. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vildagliptin Market Size and Volume Forecast by Type
9.7.1. PurityGreater than or equal to98%
9.7.2. PurityGreater than or equal to99%
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vildagliptin Demand Share Forecast, 2019-2026
10. Latin America Vildagliptin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vildagliptin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vildagliptin Market Size and Volume Forecast by Application
10.4.1. Vildagliptin Tablets
10.4.2. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vildagliptin Market Size and Volume Forecast by Type
10.7.1. PurityGreater than or equal to98%
10.7.2. PurityGreater than or equal to99%
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vildagliptin Demand Share Forecast, 2019-2026
11. Europe Vildagliptin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vildagliptin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vildagliptin Market Size and Volume Forecast by Application
11.4.1. Vildagliptin Tablets
11.4.2. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vildagliptin Market Size and Volume Forecast by Type
11.7.1. PurityGreater than or equal to98%
11.7.2. PurityGreater than or equal to99%
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vildagliptin Demand Share, 2019-2026
12. Asia Pacific Vildagliptin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vildagliptin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vildagliptin Market Size and Volume Forecast by Application
12.4.1. Vildagliptin Tablets
12.4.2. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vildagliptin Market Size and Volume Forecast by Type
12.7.1. PurityGreater than or equal to98%
12.7.2. PurityGreater than or equal to99%
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vildagliptin Demand Share, 2019-2026
13. Middle East & Africa Vildagliptin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vildagliptin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vildagliptin Market Size and Volume Forecast by Application
13.4.1. Vildagliptin Tablets
13.4.2. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vildagliptin Market Size and Volume Forecast by Type
13.7.1. PurityGreater than or equal to98%
13.7.2. PurityGreater than or equal to99%
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vildagliptin Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vildagliptin Market: Market Share Analysis
14.2. Vildagliptin Distributors and Customers
14.3. Vildagliptin Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Hikal
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Angels Pharma
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Beaukev
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Chengda Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Shanghai Acebright
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ningbo Menovo Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. EstechPharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Megafine
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Glenmark Life Sciences
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Jubilant Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Hangzhou Longshine Bio-Tech
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Zhejiang Zenitech Chemical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
